TH.TO Theratechnologies (TSX) C$4.47 intraday 16 Mar 2026: Oversold bounce watch

TH.TO stock trades at C$4.47 on the Toronto Stock Exchange intraday on 16 Mar 2026, down -4.89% from yesterday. Theratechnologies (TH.TO) dipped from a high of C$4.53 to a low of C$4.36 on light volume of 35,472 shares. This sharp intraday pullback near the 50‑day average sets a classic oversold bounce scenario. We assess fundamentals, technicals, and short‑term targets for traders looking for a measured oversold bounce entry on TSX in Canadian dollars.

Intraday move: TH.TO stock price action

Theratechnologies (TH.TO) opened at C$4.47 and is trading near the session low. The intraday decline of -4.89% widened the gap from yesterday’s close C$4.70. Volume at 35,472 shares is below the 50‑day average of 52,706, suggesting limited selling pressure so far.

One clear claim: the stock sits above its 200‑day average of C$3.32 and at the 50‑day average C$4.46, improving the odds of a short relief bounce. Traders should watch buying interest near C$4.36 and intraday VWAP to time entries.

Fundamentals snapshot and valuation

Theratechnologies Inc. is a healthcare company listed on the TSX with a market cap of C$205,530,685.00 and 45,980,019 shares outstanding. Last reported EPS is -0.26 and trailing PE is -17.19, reflecting near‑term losses. The company reports strong gross margins at 76.89% but negative net margins at -19.83%.

Revenue per share is 1.25 and free cash flow per share is -0.16. The balance sheet shows cash per share C$0.20 and a current ratio of 0.84, which calls for caution on liquidity. These metrics matter for any bounce that extends beyond a few sessions.

TH.TO stock technicals and oversold bounce setup

Technically, the stock sits at the 50‑day moving average (C$4.46) and above the 200‑day mean (C$3.32). A pullback to the intraday low C$4.36 with improving volume would confirm a short‑term oversold bounce. Average volume is 52,706 shares, so a true bounce should print higher flow.

Momentum indicators in our feed are limited, but price action suggests short sellers moved intraday. Watch for a reclaim of C$4.60 and then C$4.90 as signs the bounce is sustained. Set tight risk control because the current ratio and cash metrics increase downside risk.

Meyka AI rates TH.TO with a score out of 100 and forecast

Meyka AI rates TH.TO with a score of 71.72 out of 100 (B+) and suggests BUY. This grade factors in S&P 500 and sector comparison, industry metrics, financial growth, key ratios, forecasts, and analyst consensus. Grades are model outputs and not financial advice.

Meyka AI’s forecast model projects a 12‑month path to C$5.80. Against the current C$4.47, that implies an upside of 29.69%. Forecasts are model‑based projections and not guarantees. Use this projection with company updates and earnings flow.

Risks, catalysts, and sector context

Key risks include ongoing negative EPS, tight liquidity metrics, and reliance on specialty HIV treatments and pipeline trials. Theratechnologies lists an upcoming earnings announcement on 15 Oct 2025, which could reprice the stock. Regulatory or trial setbacks would widen downside.

Catalysts that could trigger a meaningful bounce: trial readouts, commercial growth in Trogarzo, or positive specialty licensing deals. The healthcare sector on Canadian exchanges has lagged YTD -7.38%, which caps sector‑wide momentum but also increases idiosyncratic opportunity.

Trading strategy: oversold bounce plan and price targets

For traders using an oversold bounce approach, consider a scaled entry between C$4.36 and C$4.47, with an initial profit target of C$5.20 and a secondary target near Meyka’s model C$5.80. A stop loss of 5% below entry helps manage downside in this small‑cap healthcare name.

Longer horizon investors should weigh company fundamentals and pipeline milestones before increasing exposure. Keep position sizes limited because average liquidity is modest and volatility can be elevated on news.

Final Thoughts

Intraday weakness left TH.TO stock at C$4.47 on 16 Mar 2026, presenting a measurable oversold bounce trade. The setup combines a pullback to the 50‑day average, below‑average selling volume, and a sector environment that can amplify idiosyncratic moves. Fundamentals show negative EPS -0.26, a trailing PE of -17.19, and constrained liquidity, so any bounce should be treated as tactical unless earnings or pipeline news change the outlook. Meyka AI’s forecast model projects C$5.80, roughly 29.69% above the current price, and the platform grades TH.TO 71.72/100 (B+): BUY. Use tight risk controls, scale entries between C$4.36–C$4.47, and watch volume confirmation. Remember, forecasts and grades are model outputs and not guarantees; combine them with news flow and company reports before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.